Evidence map›Paper›PMID 29967001›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2018

Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma.

Brooke L Fridley, Junqiang Dai, Rama Raghavan, Qian Li, Stacey J Winham, Xiaonan Hou, S John Weroha, Chen Wang, Kimberly R Kalli, Julie M Cunningham and 3 more

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Brooke L FridleyDepartment of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas. brooke.fridley@moffitt.org.
Junqiang DaiDepartment of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas.
Rama RaghavanDepartment of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas.
Qian LiDepartment of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas.
Stacey J WinhamDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Xiaonan HouDepartment of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
S John WerohaDepartment of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
Chen WangDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Kimberly R KalliDepartment of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
Julie M CunninghamDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-8159-3025
Kate LawrensonWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Simon A GaytherCenter for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Ellen L GoodeDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
Mentoring CoreP20GM103418 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SUSAN J. BROWN · 2012 to 2026
$63.0M
Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI NICOLE L NOLLEN · 2012 to 2026
$40.1M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Genetic Variation in the NF-kappaB Pathway and Ovarian Cancer EtiologyR01CA122443 · NCI · MAYO CLINIC ROCHESTER · PI GOODE, ELLEN L. · 2007 to 2012
$2.7M
Functional Analysis of LncRNAs in Epithelial Ovarian CancerR00CA184415 · NCI · CEDARS-SINAI MEDICAL CENTER · PI LAWRENSON, KATE · 2015 to 2017
$720k
Bayesian Integrative Clustering for Determining Molecular Based Cancer SubtyR21CA182715 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI FRIDLEY, BROOKE L · 2014 to 2015
$377k
NCI NIH HHS P30 CA076292NCI NIH HHS P30 CA168524NCI NIH HHS P50 CA136393NCI NIH HHS R00 CA184415NCI NIH HHS R01 CA122443NCI NIH HHS R21 CA182715NIGMS NIH HHS P20 GM103418
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

TranscriptomeAdenocarcinoma, Clear CellAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, EndometrioidCystadenocarcinoma, SerousFemaleFollow-Up StudiesHumansMiddle AgedOvarian NeoplasmsPrognosisSurvival RateYoung AdultBiomarkers, Tumor

Identifiers

PMID29967001
PMCPMC6719542

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.